Physician profile
Diana Boutte
NPI 1538645015
$1,360.16
in general payments reported to CMS, 2019-2025
18 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $401 · 2022: $288 · 2023: $108 · 2024: $303 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $280.13 | 2022-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $164.00 | 2021-2025 | Trintellix |
| Abbvie INC. | $139.17 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.92 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $100.61 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $84.19 | 2021-2022 | |
| Lundbeck LLC | $83.84 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $82.26 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $70.38 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $67.32 | 2021-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $42.34 | 2024-2025 | Ingrezza |
| Biogen, INC. | $27.32 | 2025 | Zurzuvae |
| Alkermes, INC. | $23.69 | 2022 | |
| Harmony Biosciences LLC | $21.03 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.90 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.62 | 2025 | Cobenfy |
| Neos Therapeutics, LP | $15.76 | 2021 | |
| Ironshore Pharmaceuticals INC. | $14.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Boutte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.